XBIO - Xenetic Biosciences, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.1700
+0.0200 (+0.93%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close2.1500
Open2.3700
Bid2.00 x 800
Ask2.17 x 900
Day's Range2.1100 - 2.3700
52 Week Range1.3690 - 8.9500
Volume29,992
Avg. Volume46,136
Market Cap20.406M
Beta (3Y Monthly)1.46
PE Ratio (TTM)N/A
EPS (TTM)-0.14
Earnings DateNov 13, 2017 - Nov 17, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.00
Trade prices are not sourced from all markets
  • What Investors Should Know About Xenetic Biosciences Inc’s (NASDAQ:XBIO) Financial Strength
    Simply Wall St.3 months ago

    What Investors Should Know About Xenetic Biosciences Inc’s (NASDAQ:XBIO) Financial Strength

    Xenetic Biosciences Inc (NASDAQ:XBIO), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is XBIO Read More...

  • Why Xenetic Biosciences Just Surged 28 Percent
    InvestorPlace6 months ago

    Why Xenetic Biosciences Just Surged 28 Percent

    Nanocap stocks are inherently risky in the stock market, but can certainly pay off for speculators when they go up. Xenetic Biosciences Inc. (NASDAQ:XBIO) surged 28%, up twofold from the $2 level the stock has been stuck at over the last year. At a closing price of $4.08 on Monday, Aug. 13, XBIO stock is still well below the $8.95 intraday high set in late-June.

  • ACCESSWIRE6 months ago

    Xenetic Biosciences Oncology Phase II Trial in Process, Pipeline Overview

    NEW YORK, NY / ACCESSWIRE / August 14, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Xenetic Biosciences, Inc. (XBIO), a clinical-stage biopharmaceutical company. The company's lead investigational product candidate is oncology therapeutic XBIO-101 (sodium cridanimod) for the treatment of progesterone resistant endometrial cancer. In 2018, an estimated 63,000 cases of endometrial cancer will be diagnosed in the U.S., and an estimated 11,000 disease-associated deaths will occur.

  • ACCESSWIRE6 months ago

    Today’s Research Reports on Stocks to Watch: Xenetic Biosciences and Antares Pharma

    NEW YORK, NY / ACCESSWIRE / August 14, 2018 / There was no news to explain the sudden jump shares of Xenetic Biosciences saw in Monday’s trading session. Shares of Antares Pharma also climbed higher despite any news. It was momentum that kept the stock going after the company announced last week that it would be working with Pfizer.

  • ACCESSWIRE8 months ago

    Upcoming FDA Catalyst and Disruptive Drug Candidate Indicate Big Near-Term Upside For This Unknown Healthcare Stock

    Dry Eye Syndrome is a huge market in the U.S., where Allergan's (AGN) Restasis has over $1.4 billion in sales annually. Investors haven't noticed, but a newly public Wize Pharma (WIZP) has an alternative drug that has been approved and used in parts of Europe for years. WIZP has U.S. rights to the drug and is running two clinical trials with results from the first to be released in the coming months.

  • Interested In Xenetic Biosciences Inc (NASDAQ:XBIO)? Here’s How It Performed Recently
    Simply Wall St.9 months ago

    Interested In Xenetic Biosciences Inc (NASDAQ:XBIO)? Here’s How It Performed Recently

    Understanding Xenetic Biosciences Inc’s (NASDAQ:XBIO) performance as a company requires examining more than earnings from one point in time. Today I will take you through a basic sense check toRead More...